{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T11:35:18Z","timestamp":1790508918808,"version":"4.1.0"},"reference-count":67,"publisher":"Impact Journals, LLC","issue":"14","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncotarget"],"published-print":{"date-parts":[[2016,4,5]]},"DOI":"10.18632\/oncotarget.7495","type":"journal-article","created":{"date-parts":[[2016,2,19]],"date-time":"2016-02-19T16:20:20Z","timestamp":1455898820000},"page":"18036-18049","source":"Crossref","is-referenced-by-count":28,"title":["Stratifying diffuse large B-cell lymphoma patients treated with chemoimmunotherapy: GCB\/non-GCB by immunohistochemistry is still a robust and feasible marker"],"prefix":"10.18632","volume":"7","author":[{"given":"Ana","family":"Batlle-L\u00f3pez","sequence":"first","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonia Gonz\u00e1lez","family":"de Villambros\u00eda","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazorra","family":"Francisco","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sefora","family":"Malatxeberria","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anabel","family":"S\u00e1ez","sequence":"additional","affiliation":[{"name":"Biobanco del Sistema Sanitario P\u00fablico de Andaluc\u00eda, Granada, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Montalban","sequence":"additional","affiliation":[{"name":"MD Anderson Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lydia","family":"S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Biotechnology Programme, Histology and Immunohistochemistry Core Unit, Spanish National Cancer Research Centre (CNIO), Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan F.","family":"Garcia","sequence":"additional","affiliation":[{"name":"Pathology, MD Anderson Cancer Center, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva","family":"Gonz\u00e1lez-Barca","sequence":"additional","affiliation":[{"name":"Department of Haematology, Hospital de Bellvitge (ICOIRO), Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s","family":"L\u00f3pez-Hern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Haematology, Hospital Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"MC","family":"Ruiz-Marcellan","sequence":"additional","affiliation":[{"name":"Departments of Pathology and Haematology, Hospital Vall d'Hebron, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manuela","family":"Mollejo","sequence":"additional","affiliation":[{"name":"Hospital Virgen de la Salud, Toledo, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlos","family":"Grande","sequence":"additional","affiliation":[{"name":"Hematology, Hospital 12 de Octubre, Madrid, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristy L.","family":"Richards","sequence":"additional","affiliation":[{"name":"Department of Hematology-Oncology, University of North Carolina School of Medicine, Chapel Hill, NC, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric D.","family":"Hsi","sequence":"additional","affiliation":[{"name":"Department of Clinical Pathology, Cleveland Clinic, Cleveland, OH, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandar","family":"Tzankov","sequence":"additional","affiliation":[{"name":"University Hospital, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"Visco","sequence":"additional","affiliation":[{"name":"Department of Hematology, San Bortolo Hospital, Vicenza, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zijun Y.","family":"Xu-Monette","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Cao","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken H.","family":"Young","sequence":"additional","affiliation":[{"name":"Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel \u00c1ngel","family":"Piris","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eulogio","family":"Conde","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Santiago","family":"Montes-Moreno","sequence":"additional","affiliation":[{"name":"Departments of Haematology and Pathology, Hospital Marques de Valdecilla, and IDIVAL, Santander, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"7892","published-online":{"date-parts":[[2016,2,19]]},"reference":[{"key":"1","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1182\/asheducation.V2012.1.402.3798516","article-title":"Paramount prognostic factors that guide therapeutic strategies in diffuse large B-cell lymphoma","volume":"2012","author":"Sehn","year":"2012","journal-title":"Hematology"},{"key":"2","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2009.26.2493","article-title":"Standard International prognostic index remains a valid predictor of outcome for patients with aggressive CD20+ B-cell lymphoma in the rituximab era","volume":"28","author":"Loeffler","year":"2010","journal-title":"Journal of clinical oncology"},{"key":"3","volume-title":"WHO Classification of Tumors of Haematopoietic and Lymphoid Tissues","author":"JW","year":"2008"},{"key":"4","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Lu","year":"2000","journal-title":"Nature"},{"key":"5","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa012914","article-title":"The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma","volume":"346","author":"Jaffe","year":"2002","journal-title":"N Engl J Med"},{"key":"6","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","author":"Shustov","year":"2015","journal-title":"Nat Med"},{"key":"7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Witzig","year":"2015","journal-title":"Journal of clinical oncology"},{"key":"8","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Wilson","year":"2009","journal-title":"Blood"},{"key":"9","article-title":"Frontline rituximab, cyclophosphamide, doxorubicin, and prednisone with bortezomib (VR-CAP) or vincristine (R-CHOP) for non-GCB DLBCL","author":"Ferhanoglu","year":"2015","journal-title":"Blood"},{"key":"10","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","article-title":"Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray","volume":"103","author":"Rosenwald","year":"2004","journal-title":"Blood"},{"key":"11","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Liu","year":"2009","journal-title":"Clinical cancer research"},{"key":"12","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"26","author":"Zu","year":"2012","journal-title":"Leukemia"},{"key":"13","first-page":"341","article-title":"Identification of outcome predictors in diffuse large B-cell lymphoma. Immunohistochemical profiling of homogeneously treated de novo tumors with nodal presentation on tissue micro-arrays","volume":"90","author":"Pileri","year":"2005","journal-title":"Haematologica"},{"key":"14","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1097\/00000478-200404000-00005","article-title":"Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma","volume":"28","author":"Perkins","year":"2004","journal-title":"The American journal of surgical pathology"},{"key":"15","doi-asserted-by":"crossref","first-page":"4135","DOI":"10.1200\/JCO.2006.05.5897","article-title":"Prognostic impact of germinal center-associated proteins and chromosomal breakpoints in poor-risk diffuse large B-cell lymphoma","volume":"24","author":"Kluin","year":"2006","journal-title":"Journal of clinical oncology"},{"key":"16","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1182\/blood-2005-04-1603","article-title":"Cell of origin, germinal center versus nongerminal center, determined by immunohistochemistry on tissue microarray, does not correlate with outcome in patients with relapsed and refractory DLBCL","volume":"106","author":"Teruya-Feldstein","year":"2005","journal-title":"Blood"},{"key":"17","unstructured":"Copie-Bergman, Gaulard, Leroy, Briere, Baia, Jais, Salles, Berger, Haioun, Tilly, Emile, Banham, Mounier, Gisselbrecht, Feugier, Coiffier, et al. Immuno-fluorescence in situ hybridization index predicts survival in patients with diffuse large B-cell lymphoma treated with R-CHOP: a GELA study. Journal of clinical oncology."},{"key":"18","doi-asserted-by":"crossref","first-page":"4836","DOI":"10.1182\/blood-2010-12-322362","article-title":"Gene-expression profiling and not immunophenotypic algorithms predicts prognosis in patients with diffuse large B-cell lymphoma treated with immunochemotherapy","volume":"117","author":"Garcia-Herrera","year":"2011","journal-title":"Blood"},{"key":"19","doi-asserted-by":"crossref","first-page":"4173","DOI":"10.1002\/cncr.27396","article-title":"Prognostic significance of MYC, BCL2, and BCL6 rearrangements in patients with diffuse large B-cell lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab","volume":"118","author":"Barista","year":"2012","journal-title":"Cancer"},{"key":"20","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1200\/JCO.2009.26.3947","article-title":"Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab","volume":"28","author":"Jack","year":"2010","journal-title":"Journal of clinical oncology"},{"key":"21","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1056\/NEJM199407143310202","article-title":"Rearrangement of the bcl-6 gene as a prognostic marker in diffuse large-cell lymphoma","volume":"331","author":"Rosenbaum","year":"1994","journal-title":"The New England journal of medicine"},{"key":"22","first-page":"2133","article-title":"The t(14;18) is associated with germinal center-derived diffuse large B-cell lymphoma and is a strong predictor of outcome","volume":"9","author":"Jack","year":"2003","journal-title":"Clinical cancer research"},{"key":"23","doi-asserted-by":"crossref","first-page":"2253","DOI":"10.1182\/blood-2012-06-435842","article-title":"MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma","volume":"121","author":"Trumper","year":"2013","journal-title":"Blood"},{"key":"24","doi-asserted-by":"crossref","first-page":"3533","DOI":"10.1182\/blood-2009-05-220095","article-title":"MYC gene rearrangements are associated with a poor prognosis in diffuse large B-cell lymphoma patients treated with R-CHOP chemotherapy","volume":"114","author":"Gascoyne","year":"2009","journal-title":"Blood"},{"key":"25","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1182\/blood-2009-03-212191","article-title":"Lymphomas with concurrent BCL2 and MYC translocations: the critical factors associated with survival","volume":"114","author":"Horsman","year":"2009","journal-title":"Blood"},{"key":"26","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1038\/modpathol.2011.147","article-title":"B-cell lymphomas with MYC\/8q24 rearrangements and IGH@BCL2\/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome","volume":"25","author":"Medeiros","year":"2012","journal-title":"Mod Pathol"},{"key":"27","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1097\/PAS.0b013e3181cd3aeb","article-title":"B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma","volume":"34","author":"Sohani","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"28","first-page":"1","article-title":"Isolated MYC cytogenetic abnormalities in diffuse large B-cell lymphoma do not predict an adverse clinical outcome","author":"Sanger","year":"2015","journal-title":"Leukemia & lymphoma"},{"key":"29","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1182\/blood-2011-01-330795","article-title":"Translocations activating IRF4 identify a subtype of germinal center-derived B-cell lymphoma affecting predominantly children and young adults","volume":"118","author":"Loeffler","year":"2011","journal-title":"Blood"},{"key":"30","doi-asserted-by":"crossref","first-page":"1515","DOI":"10.1182\/blood-2007-04-087734","article-title":"Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas","volume":"111","author":"Ye","year":"2008","journal-title":"Blood"},{"key":"31","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1182\/blood-2010-11-321554","article-title":"miRNA expression in diffuse large B-cell lymphoma treated with chemoimmunotherapy","volume":"118","author":"Martinez","year":"2011","journal-title":"Blood"},{"key":"32","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1038\/leu.2012.83","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: a report from the International DLBCL Rituximab-CHOP Consortium Program Study","volume":"26","author":"Zu","year":"2012","journal-title":"Leukemia"},{"key":"33","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","article-title":"MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program","volume":"121","author":"Bhagat","year":"2013","journal-title":"Blood"},{"key":"34","doi-asserted-by":"crossref","first-page":"3701","DOI":"10.1182\/blood-2007-09-111948","article-title":"Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma","volume":"111","author":"Staudt","year":"2008","journal-title":"Blood"},{"key":"35","article-title":"Comprehensive gene expression profiling and immunohistochemical studies support application of immunophenotypic algorithm for molecular subtype classification in diffuse large B-cell lymphoma: A report from the International DLBCL Rituximab-CHOP consortium program study","author":"Zu","year":"2012","journal-title":"Leukemia"},{"key":"36","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1136\/jclinpath-2011-200353","article-title":"Standardisation of EGFR FISH in colorectal cancer: results of an international interlaboratory reproducibility ring study","volume":"65","author":"Siena","year":"2012","journal-title":"Journal of clinical pathology"},{"key":"37","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2353\/jmoldx.2006.050083","article-title":"FISH analysis for the detection of lymphoma-associated chromosomal abnormalities in routine paraffin-embedded tissue","volume":"8","author":"Siebert","year":"2006","journal-title":"The Journal of molecular diagnostics: JMD"},{"key":"38","doi-asserted-by":"crossref","first-page":"2332","DOI":"10.1038\/sj.leu.2404856","article-title":"Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma","volume":"21","author":"Campo","year":"2007","journal-title":"Leukemia"},{"key":"39","article-title":"Rearrangements of MYC gene facilitate risk stratification in diffuse large B-cell lymphoma patients treated with rituximab-CHOP","author":"Ye","year":"2013","journal-title":"Modern pathology"},{"key":"40","doi-asserted-by":"crossref","first-page":"1828","DOI":"10.1016\/S0140-6736(11)61269-5","article-title":"Intensified chemotherapy for diffuse large B-cell lymphomas","volume":"378","author":"Vose","year":"2011","journal-title":"Lancet"},{"key":"41","article-title":"Prognostic Significance of Diffuse Large B-Cell Lymphoma Cell of Origin Determined by Digital Gene Expression in Formalin-Fixed Paraffin-Embedded Tissue Biopsies","author":"Slack","year":"2015","journal-title":"Journal of clinical oncology"},{"key":"42","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1182\/blood-2013-11-536433","article-title":"Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue","volume":"123","author":"Tubbs","year":"2014","journal-title":"Blood"},{"key":"43","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Dunphy","year":"2013","journal-title":"Haematologica"},{"key":"44","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1200\/JCO.2010.30.0368","article-title":"Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab","volume":"29","author":"Weisenburger","year":"2011","journal-title":"Journal of clinical oncology"},{"key":"45","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1158\/1078-0432.CCR-09-0113","article-title":"A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy","volume":"15","author":"Liu","year":"2009","journal-title":"Clin Cancer Res"},{"key":"46","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/bjh.12172","article-title":"Lenalidomide efficacy in activated B-cell-like subtype diffuse large B-cell lymphoma is dependent upon IRF4 and cereblon expression","volume":"160","author":"Chopra","year":"2013","journal-title":"British journal of haematology"},{"key":"47","doi-asserted-by":"crossref","first-page":"6069","DOI":"10.1182\/blood-2009-01-199679","article-title":"Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma","volume":"113","author":"Wilson","year":"2009","journal-title":"Blood"},{"key":"48","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1111\/bjh.12206","article-title":"The Bruton tyrosine kinase (BTK) inhibitor PCI-32765 synergistically increases proteasome inhibitor activity in diffuse large-B cell lymphoma (DLBCL) and mantle cell lymphoma (MCL) cells sensitive or resistant to bortezomib","volume":"161","author":"Grant","year":"2013","journal-title":"British journal of haematology"},{"key":"49","first-page":"e449","article-title":"ABC, GCB, and Double-Hit Diffuse Large B-Cell Lymphoma: Does Subtype Make a Difference in Therapy Selection?","volume":"35","author":"Czuczman","year":"2015","journal-title":"American Society of Clinical Oncology educational book \/ ASCO American Society of Clinical Oncology Meeting"},{"key":"50","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s12094-012-0926-8","article-title":"MYC oncogene in myeloid neoplasias","volume":"15","author":"Leon","year":"2013","journal-title":"Clinical & translational oncology"},{"key":"51","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.cell.2011.08.017","article-title":"BET bromodomain inhibition as a therapeutic strategy to target c-Myc","volume":"146","author":"Bergsagel","year":"2011","journal-title":"Cell"},{"key":"52","doi-asserted-by":"crossref","first-page":"2843","DOI":"10.1182\/blood-2012-02-413021","article-title":"BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia","volume":"120","author":"Weinstock","year":"2012","journal-title":"Blood"},{"key":"53","doi-asserted-by":"crossref","first-page":"16669","DOI":"10.1073\/pnas.1108190108","article-title":"Targeting MYC dependence in cancer by inhibiting BET bromodomains","volume":"108","author":"Sims","year":"2011","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"54","doi-asserted-by":"crossref","first-page":"4400","DOI":"10.1182\/blood-2012-05-428466","article-title":"Expression of Myc, but not pSTAT3, is an adverse prognostic factor for diffuse large B-cell lymphoma treated with epratuzumab\/R-CHOP","volume":"120","author":"Witzig","year":"2012","journal-title":"Blood"},{"key":"55","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1186\/1471-2407-14-911","article-title":"Overexpression of sphingosine-1-phosphate receptor 1 and phospho-signal transducer and activator of transcription 3 is associated with poor prognosis in rituximab-treated diffuse large B-cell lymphomas","volume":"14","author":"Jeon","year":"2014","journal-title":"BMC cancer"},{"key":"56","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1084\/jem.189.1.63","article-title":"STAT3 is required for the gp130-mediated full activation of the c-myc gene","volume":"189","author":"Hirano","year":"1999","journal-title":"The Journal of experimental medicine"},{"key":"57","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1634\/theoncologist.2013-0407","article-title":"STAT3 inhibitors: finding a home in lymphoma and leukemia","volume":"19","author":"Hong","year":"2014","journal-title":"The oncologist"},{"key":"58","doi-asserted-by":"crossref","first-page":"5113","DOI":"10.1158\/1078-0432.CCR-14-0683","article-title":"Clinical implications of phosphorylated STAT3 expression in De Novo diffuse large B-cell lymphoma","volume":"20","author":"Choi","year":"2014","journal-title":"Clinical cancer research"},{"key":"59","doi-asserted-by":"crossref","first-page":"3460","DOI":"10.1200\/JCO.2011.41.4342","article-title":"Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"M\u00f8ller","year":"2012","journal-title":"J Clin Oncol"},{"key":"60","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","article-title":"Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"30","author":"Rimsza","year":"2012","journal-title":"Journal of clinical oncology"},{"key":"61","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3324\/haematol.2012.066209","article-title":"Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study","volume":"98","author":"Dunphy","year":"2013","journal-title":"Haematologica"},{"key":"62","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1038\/leu.2015.43","article-title":"Different biological risk factors in young poor-prognosis and elderly patients with diffuse large B-cell lymphoma","volume":"29","author":"Cogliatti","year":"2015","journal-title":"Leukemia"},{"key":"63","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1007\/s40291-012-0003-6","article-title":"Biomarkers of therapeutic response to BCL2 antagonists in cancer","volume":"16","author":"Chyla","year":"2012","journal-title":"Molecular diagnosis & therapy"},{"key":"64","doi-asserted-by":"crossref","first-page":"96","DOI":"10.3324\/haematol.2009.007203","article-title":"Correlations between BCL6 rearrangement and outcome in patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP","volume":"95","author":"Steidl","year":"2010","journal-title":"Haematologica"},{"key":"65","doi-asserted-by":"crossref","first-page":"4207","DOI":"10.1182\/blood-2005-10-4222","article-title":"Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study","volume":"107","author":"Gascoyne","year":"2006","journal-title":"Blood"},{"key":"66","doi-asserted-by":"crossref","first-page":"5509","DOI":"10.1182\/blood-2008-02-136374","article-title":"Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP","volume":"111","author":"Lossos","year":"2008","journal-title":"Blood"},{"key":"67","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/j.molmed.2014.03.001","article-title":"Breaking bad in the germinal center: how deregulation of BCL6 contributes to lymphomagenesis","volume":"20","author":"Melnick","year":"2014","journal-title":"Trends in molecular medicine"}],"container-title":["Oncotarget"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7495","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T15:59:47Z","timestamp":1594828787000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.oncotarget.com\/lookup\/doi\/10.18632\/oncotarget.7495"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,19]]},"references-count":67,"journal-issue":{"issue":"14","published-print":{"date-parts":[[2016,4,5]]}},"alternative-id":["7495","26910115"],"URL":"https:\/\/doi.org\/10.18632\/oncotarget.7495","relation":{},"ISSN":["1949-2553"],"issn-type":[{"value":"1949-2553","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,19]]}}}